Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2038-2044

  Sørensen, Rikke Bæk ^a   Køllgaard, Tania ^a   Andersen, Rikke Sick ^a   Van Den Berg, Joost Huibert ^a   Svane, Inge Marie ^a   Straten, Per Thor ^a   Andersen, Mads Hald ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER PATIENT; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; MOLECULAR RECOGNITION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HCT116 CELLS; HLA-A2 ANTIGEN; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; K562 CELLS; KIDNEY NEOPLASMS; MELANOMA; NEOPLASMS; PEPTIDES; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952762101     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3403     Document Type: Article

References (20)

1. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27:3889-900. (Pubitemid 351913639)
2. Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle 2009;8:1818-9.
3. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40. (Pubitemid 46345506)
4. Banerjee T, DuHadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008;27:2851-7. (Pubitemid 351620442)
5. Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008;51:4968-77.
6. Kumar S, Malachowski WP, DuHadaway JB , LaLonde JM, Carroll PJ, Jaller D, et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008;51:1706-18. (Pubitemid 351438852)
7. Metz R, DuHadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, et al. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther 2010;9:1864-71.
8. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801. (Pubitemid 46192220)
9. Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7. (Pubitemid 47206533)
10. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009;208:781-7.
11. Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 2009;4:e6910.
12. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006;1:1120-32.
13. Andersen MH, Pedersen LO, Becker JC, thor Straten P. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res 2000;61:869-72.
14. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med 2006;12:246-51. (Pubitemid 43214754)
15. Sorensen RB, Hadrup SR, Kollgaard T, Svane IM, Thor SP, Andersen MH. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother 2007;56:527-33.
16. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9. (Pubitemid 40460560)
17. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic Tlymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50. (Pubitemid 46224173)
18. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396:203-13. (Pubitemid 46818792)
19. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-6. (Pubitemid 36841977)
20. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor SP, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. In press 2011.